30 closest matches · ranked by relevance
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy — 0; 1; 4…
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Brainstem Glioma
Primary: Progression-free Survival — 4.9 Months
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Brain and Central Nervous System Tumors
Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months
High Grade Glioma
Primary: Response Rate
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Childhood High-grade Cerebellar Astrocytoma · Childhood High-grade Cerebral Astrocytoma · Recurrent Childhood Anaplastic Astrocytoma
Primary: Objective Response to Cilengitide — 1; 23 participants
Childhood Cerebral Anaplastic Astrocytoma · Childhood Oligodendroglioma · Childhood Spinal Cord Neoplasm
Primary: Objective Response Rate Sustained for ≥ 8 Weeks — 0; 0; 0; 0 participants
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) of Vorinostat — 230 mg/m^2
Juvenile Pilocytic Astrocytomas · Optic Pathway Gliomas
Primary: Number of Children Responding to Treatment — 0; 0; 5 Participants
Anaplastic Astrocytoma · Brain Stem Glioma · Childhood Mixed Glioma
Primary: Maximum-tolerated Dose of Veliparib Defined as Highest Dose Level With Fewer Than 2 Dose Limiting Toxicities in 6 Patients as Assessed by the National Cancer Institute…
Untreated Childhood Anaplastic Astrocytoma · Untreated Childhood Anaplastic Oligodendroglioma · Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy — 2; 0; 1 Participants
Adult Anaplastic Astrocytoma · Adult Giant Cell Glioblastoma · Adult Gliosarcoma
Primary: Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma — 0; 0; NA; 0 DLTs
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Glioma
Primary: Progression-free Survival
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants